Select Revenue HighlightsWorldwide sales were $11.5 billion for the third quarter of 2012, a decrease of 4 percent. Excluding the unfavorable impact of foreign exchange, sales were comparable with the third quarter of 2011. Strong growth of key products offset the negative impact of the August 2012 loss of market exclusivity for SINGULAIR (montelukast sodium) in the United States. The following table reflects sales of the company's top pharmaceutical products, as well as total sales of animal health and consumer care products.
|$ in millions||Third Quarter 2012||Third Quarter 2011||Change|
|PROQUAD, M-M-R II and VARIVAX||396||391||1%|